Search

The present status of monoamine oxidase inhibitors in the treatment of depression is reviewed. With adequate doses they are effective antidepressants, but dosages have in the past been too low. Provided proper dietary precautions are taken, the incidence of fatality from dietary interactions is very small and should not deter doctors from using these drugs, especially in those depressed patients who do not respond to tricyclic-type antidepressants. The present status of combining monoamine oxidase inhibitors with tricyclics is discussed, as are the newer specific inhibitors particularly clorgyline and deprenyl. [ABSTRACT FROM AUTHOR]

The article presents a comparative clinical trial concerning the efficacy of diazepam and amylobarbitone in the treatment of anxiety. Both amylobarbitone and diazepam were given to psychiatric out-patients with symptoms of anxiety three times a day for two weeks. Findings reveal that both doctors and patients prefer diazepam, however, few side-effects are encountered. It suggests that diazepam is more effective in relieving anxiety symptom, and is closely related to chlordiazepoxide, which is superior to amylobarbitone for anxiety medication.